Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
SF / Stifel Financial Corp. S-4/A

9h sec.gov
S-4/A Table of Contents As filed with the Securities and Exchange Commission on July 17, 2018. Registration No. 333-225729
SF

0
MOVES- MUFG, KBW, Ernst & Young, Willis Towers

2018-07-16 reuters
July 16 (Reuters) - The following financial services industry appointments were announced on Monday. To inform us of other job changes, email [email protected]
SF SFN SFB SF.PRA

0
MOVES-KBW hires Evercore's Rajib Sarkar as managing director

2018-07-16 reuters
(Reuters) - Keefe, Bruyette & Woods Inc, a subsidiary of Stifel Financial Corp (SF.N), said Rajib Sarkar has joined the broker-dealer as managing director in the insurance investment banking group.
SF SFN SFB SF.PRA

3
Moving Average Crossover Alert: Stifel Financial (SF)

2018-07-16 zacks
Stifel Financial Corp. (SF - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for SF broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
GTT SF SFN SFB SF.PRA

0
Trade 'Dispute' Not Trade 'War' - Q2 2018 Market Commentary

2018-07-04 seekingalpha
The 2nd quarter of 2018 saw global equity markets lose some ground from the first quarter, much of it attributed to the growing trade war dispute that is taking shape.
SF SFN SFB SF.PRA

10
6 Reasons to Include Stifel Financial (SF) in Your Portfolio

2018-06-29 zacks
Stifel Financial Corp. (SF - Free Report) appears to be a promising bet now given its solid organic growth and efforts to expand inorganically. In addition, interest rate hikes and improving economy are anticipated to further stabilize its top line.
LPLA GM.WS.A GM.WS.B SF ITG GM.WS.C SFN GM GM.WSB PII SFB SF.PRA

8
5 Reasons That Make Evercore (EVR) a Good Investment Option

2018-06-28 zacks
Evercore (EVR - Free Report) seems to be an attractive stock on the back of its top-line strength and solid balance sheet position. Further, its earnings growth prospects and efforts to enhance shareholder value are encouraging.
LPLA SF ITG SFN SFB SF.PRA

7
E*TRADE Rallies 10.5% Quarter to Date: What's Driving It?

2018-06-28 zacks
During the Q1 earnings season, financial stocks put up a decent show. Notably, one such investment bank — E*TRADE Financial Corporation (ETFC - Free Report) — has rallied 10.5% quarter to date, significantly outperforming the industry’s decline of nearly 6%. This price performance is backed by the gradually improving operating environment and rate hike scenario, which is beneficial for brokerage business.
LPLA ETFC SF SFN SFB SF.PRA

50
Paychex, Inc. (PAYX) CEO Martin Mucci on Q4 2018 Results - Earnings Call Transcript

2018-06-27 seekingalpha
Welcome everyone, and thank you for standing by. At this time, all participants are in a listen-only mode until the question-and-answer session of today's conference. [Operator Instructions] This call is being recorded. If you have any objections, you may disconnect now.
WFCNP DB MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV PAYX SF.PRA WFC WFC.WS SF SFN MS.PRI MS.PRK SFB

18
MOVES-KBW names four new managing directors

2018-06-25 reuters
June 25 (Reuters) - Boutique investment bank KBW, a unit of Stifel Financial Corp, on Monday named four new managing directors.
MS.PRI MS.PRK MS.PRE SF MS.PRF SFN MS.PRG MS MS.PRA SFB SF.PRA

15
Nomura (NMR) Trims Global Markets Jobs in US to Reduce Costs

2018-06-25 zacks
Per a Bloomberg article, Nomura Holdings (NMR - Free Report) has laid off about 28 sales and trading employees from its U.S. branch. The job cuts are expected to be linked with cost cutting targets to combat low volatility prevailing in the market.
NMR DB 8604 N33 ETFC NRSCF SF SFN SFB SF.PRA

1
SF / Stifel Financial Corp. 11-K

2018-06-22 sec.gov
11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
SF

6
Nearly 2,000 People Attend Stifel’s Inaugural Cross Sector Insight Conference

2018-06-21 globenewswire
ST. LOUIS, June 21, 2018 (GLOBE NEWSWIRE) -- Following a hugely successful inaugural event, Stifel Financial Corp. (NYSE:SF) today announced plans to host another Cross Sector Insight Conference next year. The event will be held June 10-12, 2019 at the InterContinental Hotel in Boston.
SF SFN SFB SF.PRA

2
SF / Stifel Financial Corp. 8-K (Current Report)

2018-06-20 sec.gov
sf-corresp_16.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SF

1
SF / Stifel Financial Corp. S-4

2018-06-20 sec.gov
S-4 Table of Contents As filed with the Securities and Exchange Commission on June 19, 2018. Registration No. 333- <
SF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to SF / Stifel Financial Corp. on message board site Silicon Investor.

Microsoft Corp. - Moderated (MSFT) Salesforce.com
Indications -- obesity/erectile dysfunction DEPO ride the coattails of a successful activist investor.
Safenet - The Name In VPN Security (SFNT) dynaCERT Inc. (DYA.V) (DYFSF) carbon emission red. u0026 fuel sa
Swift Energy (SFY) Nuvilex inc (former EFSF eFoodSafety.com
ESFS - Eco-Safe Systems USA, Inc. Microsoft (MSFT) Trash Talk
CUSIP: 860630102